Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Overview of attention for article published in The Lancet, January 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#9 of 42,340)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 725 news outlets
blogs: 59 blogs
policy: 10 policy sources
twitter: 10685 X users
patent: 13 patents
facebook: 27 Facebook pages

wikipedia: 36 Wikipedia pages
reddit: 4 Redditors
f1000: 1 research highlight platform
q&a: 1 Q&A thread
video: 27 YouTube creators

Citations

dimensions_citation: 3974 Dimensions

Readers on

mendeley: 4373 Mendeley

Summary News Blogs Policy documents X Patents Facebook Wikipedia Reddit Research highlights Q&A YouTube Dimensions citations

So far, Dimensions has found 3,974 publications that cite this research output.

3,974

The most recent citing publications are shown below. View all 3,974 publications that cite this research output on Dimensions.

Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study – final study results

Article in IJID Regions (March 2024)

28 COVID-19

Book chapter (January 2024)

Chapter 13 The effect of COVID-19 on cancer immunotherapy and cancer care

Book chapter (January 2024)